Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

61. Individual support of nurses using electronic medicine monitors can improve HIV treatment

Individual support of nurses using electronic medicine monitors can improve HIV treatment Individual support of nurses using electronic medicine monitors can improve HIV treatment Discover Portal Discover Portal Individual support of nurses using electronic medicine monitors can improve HIV treatment Published on 10 October 2017 doi: Use of electronic pill bottles that record when they are opened and follow-up discussion of the printed readouts with nurses improved HIV outcomes. It is thought (...) that patients became more reliable in taking the medication, which can have complicated scheduling. Overall, the HIV virus in the blood and the risk of treatment failure were lower in the group of patients who had access to this intervention compared to regular care. In addition to being more effective, the programme also reduced the estimated lifetime cost and disease burden per patient, considering quality and quantity of life lived. The readouts were used to help focus attention on any patterns

2019 NIHR Dissemination Centre

62. Self-testing kits increase overall HIV testing uptake in men who have sex with men

Self-testing kits increase overall HIV testing uptake in men who have sex with men Self-testing kits increase overall HIV testing uptake in men who have sex with men Discover Portal Discover Portal Self-testing kits increase overall HIV testing uptake in men who have sex with men Published on 6 February 2018 doi: Frequency of HIV testing in men who have sex with men may be increased by one additional test in a six month period when self-testing kits are used. Self-testing kits allow people (...) and support following an HIV diagnosis are of great importance and should include partner notification. Self-testing kits are available in the UK online from and are recommended by Public Health England. Share your views on the research. Why was this study needed? An estimated 89,400 people in the UK are living with HIV according to 2016 figures. The annual rate of new diagnoses is starting to decline, falling from 6,286 in 2015 to 5,164 in 2016. Over half of cases are in men who have sex with men (MSM

2019 NIHR Dissemination Centre

63. Single therapy an option for adults with suppressed HIV

Single therapy an option for adults with suppressed HIV Single therapy an option for adults with suppressed HIV Discover Portal Discover Portal Single therapy an option for adults with suppressed HIV Published on 28 June 2016 doi: For adults with HIV who have achieved a low level of the HIV virus after initial treatment, further treatment with a protease inhibitor alone instead of standard triple drug therapy does not reduce future drug options. It is also cost-effective for long-term (...) management of HIV. In this large NIHR funded trial, switching to single therapy after the virus level is suppressed did not lead to treatment resistance compared to triple therapy, as earlier evidence had suggested. A return to detectable levels, called a rebound increase, was ten-fold higher on single therapy but this was managed with a change in drug regime. There was no difference between the groups in terms of quality of life, disease complications or side effects up to five years. Single therapy

2019 NIHR Dissemination Centre

64. Methods to estimate the number of people living with undiagnosed HIV

Methods to estimate the number of people living with undiagnosed HIV Methods to estimate the number of people living with undiagnosed HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Methods to estimate the number of people living with undiagnosed HIV Methods to estimate the number of people living with undiagnosed HIV , , , , , , , Questions How do we know how many people are living with undiagnosed HIV infection? What population groups make up people living (...) with undiagnosed HIV infection? Key take-home messages At the end of 2016, the Public Health Agency of Canada estimated that 14% of 63,110 individuals living with HIV in Canada were undiagnosed (1). Different types of data can be used across a variety of methodologies to estimate the undiagnosed proportion of people living with HIV (2, 3). The proportion of individuals living with HIV in Canada who were undiagnosed in 2016 was estimated using a complex statistical method known as “back-calculating”, which

2019 Ontario HIV Treatment Network

65. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) , Correlation Network, Choices Support Center, Netherlands Jens Lundgren, CHIP/Region H, Denmark Jessika Deblonde, Sciensano, Belgium Jordi Casabona, Center of Epidemiological Studies on HIV and STI in Catalonia (CEEISCAT), Spain Justyna Kowalska, Medical University of Warsaw, Poland Kristi Rüütel, National Institute for Health Development, Estonia Maria Axelsson, Public Health Agency of Sweden, Sweden Maria Elena Tosti, Istituto Superiore di Sanità, Italy Matthew Hickman, University of Bristol, United

2019 European Centre for Disease Prevention and Control - Public Health Guidance

66. Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1)

Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet Reference number: 2850 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX (...) /rilpivirine (Juluca ® ? ) 50 mg/25 mg film-coated tablet 1.0 KEY FACTS Assessment details Dolutegravir/rilpivirine (Juluca ® ? ) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA 50 copies/ml but lower than 200 copies/ml in the past 12 months 11 . Previous antiretroviral therapy regimens of two nucleoside reverse transcriptase inhibitors plus a third medicine (a non-nucleoside reverse transcriptase inhibitor, an integrase

2019 All Wales Medicines Strategy Group

67. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

68. Assessment of hydrolytic enzyme activity of Candida albicans isolated from the oral cavity of HIV infected and non-infected individuals: a systematic review and meta-analysis

Assessment of hydrolytic enzyme activity of Candida albicans isolated from the oral cavity of HIV infected and non-infected individuals: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

69. A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection

A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

70. Treatment regimens for progressive disseminated histoplasmosis in people living with HIV

Treatment regimens for progressive disseminated histoplasmosis in people living with HIV Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

71. The earlier the better: in what ways are men who have sex with men being targeted for acute HIV infection screening in different countries?

The earlier the better: in what ways are men who have sex with men being targeted for acute HIV infection screening in different countries? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

72. Association between HIV infection and multidrug-resistant tuberculosis in Africa and Asia :a systematic review and meta-analysis

Association between HIV infection and multidrug-resistant tuberculosis in Africa and Asia :a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

73. Safety and efficacy of immune checkpoint inhibitors in HIV infected patients with or without cancer: a systematic review

Safety and efficacy of immune checkpoint inhibitors in HIV infected patients with or without cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

74. The impact of sexual orientation and HIV-related stigma on the psychological wellbeing of gay and bisexual males: a systematic review

The impact of sexual orientation and HIV-related stigma on the psychological wellbeing of gay and bisexual males: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

75. The safety and side effect profile of metformin use in HIV-infected persons on anti-retroviral therapy

The safety and side effect profile of metformin use in HIV-infected persons on anti-retroviral therapy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

76. Risk of invasive salmonella infection among HIV exposed populations: a systematic review and meta-analysis

Risk of invasive salmonella infection among HIV exposed populations: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

77. The effectiveness of motivational interviewing (MI) on reducing HIV-related risky behaviors among men who have sex with men (MSM): a systematic review and meta-analysis

The effectiveness of motivational interviewing (MI) on reducing HIV-related risky behaviors among men who have sex with men (MSM): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

78. Fracture incidence in HIV

Fracture incidence in HIV Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

79. Factors associated with HIV-1 low level viraemia in patients on effective anti-retroviral therapy

Factors associated with HIV-1 low level viraemia in patients on effective anti-retroviral therapy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

80. Effectiveness of cognitive behavioural interventions for depression and anxiety in those with HIV: a systematic review of RCTs

Effectiveness of cognitive behavioural interventions for depression and anxiety in those with HIV: a systematic review of RCTs Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO